In colorectal cancer (CRC), dual inhibition of LILRB1 and PD-L1 leads to enhanced dendritic cell activation, improved cross-presentation of tumor antigens, and greater expansion of tumor-specific CD8+ T cells, outperforming either monotherapy alone (157, 161). Here, CD8A is linked to neoplasm.